Tag Archives: Trodelvy

FDA Approves Trodelvy, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival

FOSTER CITY, Calif.–(BUSINESS WIRE)–Apr. 7, 2021– Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to Trodelvy® (sacituzumab govitecan-hziy) for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. The… Read More »

ESMO: New Trodelvy breast, bladder cancer data show why Gilead’s going big for Immunomedics

Compared with the spate of multibillion-dollar buyouts last year, biopharma M&A has been relatively quiet in 2020—until last week, when Gilead Sciences surprised the market with its $ 21 billion purchase of Immunomedics. Now, two sets of new cancer data from Immunomedics’ first-in-class antibody-drug conjugate Trodelvy offer a glimpse into why Gilead paid such big money… Read More »